Detailed entry information

Protein Information (annotations from UniProt)

Database IDHIV0008194
UniProt IDP51636
Primary gene name(s)CAV2
Synonym gene name(s)unknown
Protein nameCaveolin-2
Protein functionMay act as a scaffolding protein within caveolar membranes. Interacts directly with G-protein alpha subunits and can functionally regulate their activity. Acts as an accessory protein in conjunction with CAV1 in targeting to lipid rafts and driving caveolae formation. The Ser-36 phosphorylated form has a role in modulating mitosis in endothelial cells. Positive regulator of cellular mitogenesis of the MAPK signaling pathway. Required for the insulin-stimulated nuclear translocation and activation of MAPK1 and STAT3, and the subsequent regulation of cell cycle progression, By similarity. {ECO:0000250, ECO:0000269|PubMed:15504032, ECO:0000269|PubMed:18081315}.
Subcellular locationNucleus. Cytoplasm. Golgi apparatus membrane;
Peripheral membrane protein. Cell membrane;
Peripheral membrane protein. Membrane, caveola;
Peripheral membrane protein. Note=Potential hairpin-like structure in the membrane. Membrane protein of caveolae. Tyr-19-phosphorylated form is enriched at sites of cell-cell contact and is translocated to the nucleus in complex with MAPK1 in response to insulin, By similarity. Tyr-27-phosphorylated form is located both in the cytoplasm and plasma membrane. CAV1-mediated Ser-23-phosphorylated form locates to the plasma membrane. Ser-36-phosphorylated form resides in intracellular compartments. {ECO:0000250}.
ECO codeClick here for more information.
Amino acid sequence
FASTA format: P51636
Gene Ontology
(Biological Process)
Complete annatation
caveola assembly [GO:0070836];
endoplasmic reticulum organization [GO:0007029];
insulin receptor signaling pathway [GO:0008286];
mitochondrion organization [GO:0007005];
negative regulation of endothelial cell proliferation [GO:0001937];
negative regulation of transforming growth factor beta receptor signaling pathway [GO:0030512];
positive regulation by host of viral process [GO:0044794];
positive regulation by host of viral release from host cell [GO:0044791];
positive regulation of dopamine receptor signaling pathway [GO:0060161];
positive regulation of endothelial cell proliferation [GO:0001938];
positive regulation of GTPase activity [GO:0043547];
positive regulation of MAPK cascade [GO:0043410];
protein oligomerization [GO:0051259];
receptor-mediated endocytosis of virus by host cell [GO:0019065];
regulation of mitotic nuclear division [GO:0007088];
skeletal muscle fiber development [GO:0048741];
vesicle docking [GO:0048278];
vesicle fusion [GO:0006906];
vesicle organization [GO:0016050]
Gene Ontology
(Molecular Function)
Complete annatation
D1 dopamine receptor binding [GO:0031748];
protein homodimerization activity [GO:0042803]
Gene Ontology
(Cellular Component)
Complete annatation
acrosomal membrane [GO:0002080];
caveola [GO:0005901];
cytoplasmic vesicle [GO:0031410];
extrinsic component of cytoplasmic side of plasma membrane [GO:0031234];
focal adhesion [GO:0005925];
Golgi apparatus [GO:0005794];
Golgi membrane [GO:0000139];
integral component of plasma membrane [GO:0005887];
intracellular [GO:0005622];
membrane [GO:0016020];
membrane raft [GO:0045121];
nucleus [GO:0005634];
perinuclear region of cytoplasm [GO:0048471];
plasma membrane [GO:0005886];
protein complex [GO:0043234];
transport vesicle [GO:0030133]
Protein-protein interaction107306
Phylogenetic treeP51636
HIV replication factor status Zhou et al., Cell. Host. Microbe., 2008
Brass et al., Science, 2008
Smith et al., J. Immunol, 2010
gene status
Lu et al., J. Virol., 2011
      Folds changes 8h: unknown; Folds changes 16h: unknown; Tested: unknown;
Schoggins JW and Rice CM, Curr. Opin. Virol., 2011
      Targeted viruses: unknown
      Viral life cycle: unknown
      Mechanism related to antiviral activity: unknown
Anti-viral restriction factor Liu et al., Retrovirology, 2011
      unknown (Triplicates)

Gene Expression Profile       top

            Up-regulated;            Down-regulated

For brief introduction to each study, please go to the help page.

Gene expression during HIV latency

(1). Mohammadi et al., PLoS Pathog., 2014

Differentially expressed transcripts (Pairwise) during latency and subsequent viral reactivation using several agents - Primary CD4+ T-cell based model

DMSO: Dimethyl suloxyde (negative control) - 0.0033% final
SAHA: Vorinostat (Histone deacetylase inhibitor) - 0.5 μM
CD3: TCR Stimulation by IL-2+ antiCD3/anti-CD28 antibodies
IL7: Interleukin-7 based stimulation
DISU: Disulfiram (alcohol dehydrogenase inhibitor) - 0.5 μM
AZA: 5-azacytidine (AZA; DNA methylation inhibitor) - 1 μM
Experimental Condition Log2 Fold Change P value Adjusted P value
AZA vs. CD3-1.33907944152440.1113642157344270.191913460584635
AZA vs. DISU-0.5255003043825630.5545002862840790.948109949574206
AZA vs. IL7-0.5382200441424030.4662933479628960.999311006273513
AZA vs. SAHA-0.3157342323459510.7091320536137330.918461773964516
DISU vs. CD30.8017776656349370.4360113715087010.567567825053727
DISU vs. IL7-0.02141957873889480.9798433608993220.997754944136459
DISU vs. SAHA0.2083891843980350.8229404987826990.954457236048875
DMSO vs. AZA-0.06663687105791620.9289366578808711
DMSO vs. CD31.253384607422080.1023442329166680.174118110546539
DMSO vs. DISU0.4546202343091550.5945345875633320.937098979571498
DMSO vs. IL7-0.462830491065730.5024593383015920.886421465631531
DMSO vs. SAHA-0.255663441973370.7516029449655480.927243948697084
HIV vs. Mock in Activation-0.6125413347754770.5607724301067850.999983755607037
HIV vs. Mock in Latency-0.310092482842050.554445840397390.999834320637052
IL7 vs. CD30.8095745447066740.2893437856463630.426572660509353
SAHA vs. CD30.9948712357233820.2921948219310280.405542085697236
SAHA vs. IL70.2166179388216330.786714789167070.906577381844233
(2). Iglesias-Ussel et al., J. Virol., 2013

Up and Downregulated transcripts during Latency (Latently infected CD4+ T cells vs Uninfected)- Primary CD4+Tcell based model
Log2 Fold Change P Value
unknown unknown

Gene expression during HIV infection and replication

(1). Imbeault et al., PloS Pathog., 2012

Transcriptomic profiling of HIV-1 infected CD4+ T cells - Primary CD4+ T cells
Experiment type Log2 Fold Change P Value Adjusted P Value
Infected vs. Mock unknown unknown unknown
Infected vs. Bystander unknown unknown unknown
(2). Lefebvre et al., J. Virol., 2011

Transcriptome analysis of T-cell line (Sup T1)
Log2 Fold Change unknown
(3). Li et al., J. Immunol., 2013

Lymphatic tissue
Acute Fold Change Acute P Value Asymt Fold Change Asypt P Value AIDS Fold Change AIDS P Value
unknown unknown unknown unknown unknown unknown
(4). Chang et al., MBio., 2011

Transcriptome analysis of T-cell line (Sup T1)

Derived from Sherrill-Mix et al., BMC Retrovirol., 2015 cross validation
Up-regulated (True) unknown
(5). Sherrill-Mix et al., BMC Retrovirol., 2015

Deep RNA-seq analysis of primary human T cell infected with low passage HIV isolate HIV89.6 - Primary CD4+ T cell based
Test Status Log2 Fold Change P Value
OK -1.25255 0.000305467
(6). Rotger et al., PLoS Pathog., 2010

Genome-wide mRNA expression of CD4+ T cells from HIV-infected patient
(Genes differentially expressed (at adjusted p<0.01) according to the empirical Bayes approach)
Log2 Fold Change P Value
unknown unknown

Proteomic/Transcriptomics studies indicating differentially expressed genes mediated by HIV

(1). Greenwood et al., Elife, 2016

Activated (CD3/CD28) Primary human CD4+ T cells infected with pNL4-3-dE-EGFP. The table shows the complete (unfiltered) TMT (tandem mass tag)-based proteomic time course dataset
6 h 24 h 48 h 72 h RTi
unknown unknown unknown unknown unknown
(2). Navare et al., Virology, 2012

SUP-T1 cell line
FC-4hpi P-value FC-8hpi P-value FC-20hpi P-value Category
unknown unknown unknown unknown unknown unknown unknown
(3). Hyrcza et al., J. Virolo., 2007

Primary human CD4+ and CD8+ T Cells
Affymetrix Prob ID Fold Change In CD8? Category